# Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

> **NCT06860386** · PHASE2 · SUSPENDED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 75 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT06860386
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-02-25
- **Primary completion:** 2026-09
- **Final completion:** 2028-02
- **Target enrollment:** 75 (ESTIMATED)
- **Why stopped:** Funding unavailable
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860386, "Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06860386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*